Clinical trials: sponsored by Merck Sharp & Dohme LLC
Streptococcus Pneumonia, Controlled Human Infection
Experimental Human Pneumococcal Challenge With SPN3
The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past…
- Trial name
- Challenge3 (NCT05535868)
- Testing
- Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3), Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Healthy
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another…
- Trial name
- NCT07232589
- Testing
- Nemtabrutinib, Diltiazem
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor.
- Trial name
- NCT05952453
- Testing
- Carboplatin, olaparibp, embro
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma Multiforme, Astrocytoma, Grade IV
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer.
- Trial name
- TCaP (NCT06157541)
- Testing
- Allogeneic cytomegalovirus-specific T cells, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 58 people
- Sponsor
- Queensland Institute of Medical Research
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been…
- Trial name
- NCT04165096
- Testing
- Pembrolizumab, Boserolimab, MK-4830
- Where
- 39 sites in United States, Hungary and 5 more
- Volunteers
- 128 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
The goal of this clinical trial is to learn about IOS-1002 in patients with solid tumors. The main questions it aims to answer are: To determine the safety and tolerability of various doses of IOS-1002 administered alone and/or…
- Trial name
- NCT05763004
- Testing
- IOS-1002, IOS-1002 + KEYTRUDA® (pembrolizumab)
- Where
- 5 sites in Australia
- Volunteers
- 47 people
- Sponsor
- ImmunOs Therapeutics AG
Healthy
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT07548606
- Testing
- Opevesostat, Prednisone, Fludrocortisone acetate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Trial name
- NCT04219254
- Testing
- BI1206
- Where
- 26 sites in United States, Georgia and 5 more
- Volunteers
- 197 people
- Sponsor
- BioInvent International AB
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC)…
- Trial name
- NCT02220894
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 1,274 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Bladder Cancer
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
This is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach
- Trial name
- FIDELIO (NCT07663747)
- Testing
- Enfortumab Vedotin, Pembrolizumab, Radiation
- Where
- 3 sites in Netherlands
- Volunteers
- 56 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Cancer, Cervical Cancer
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
This is a multi-centre Phase I dose finding and proof-of-concept study of the combination of ASTX660 together with Pembrolizumab with expansion cohorts testing preliminary efficacy in immune-refractory cancers, triple negative…
- Conditions
- Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
- Trial name
- ASTEROID (NCT05082259)
- Testing
- ASTX660, Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Angiosarcoma of Skin, Angiosarcoma Metastatic
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Cutaneous angiosarcoma is a rare cancer for which effective treatment has not been developed sufficiently. Still, because it often occurs in elderly people, the number of patients is increasing due to the aging population.
- Trial name
- PLAS (NCT06673628)
- Testing
- Pembrolizumab plus Lenvatinib
- Where
- 6 sites in Japan
- Volunteers
- 38 people
- Sponsor
- National Cancer Center, Japan
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Solid Tumors
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable)…
- Trial name
- NCT04123366
- Testing
- Olaparib, Pembrolizumab
- Where
- 135 sites in United States, Argentina and 21 more
- Volunteers
- 333 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05726370
- Testing
- Pembrolizumab, CISPLATIN, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Health Care Utilization
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services…
- Trial name
- NCT06326567
- Testing
- C4 Program
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Timothy Mullett
HIV Infection
MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)
This study will examine if at least one dose level of MK-4646 can lower HIV-1 viral load in a person's blood by a certain amount.
- Trial name
- NCT07042945
- Testing
- MK-4646
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Triple Negative Breast Cancer, Metastatic Breast Cancer
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+.
- Trial name
- NCT03362060
- Testing
- Pembrolizumab, PVX-410
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.